Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rechARge phase 3 study of BMS-986365 versus investigator's choice in metastatic castration-resistant prostate cancer
jRCT2031250827Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of BMS-986365 in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Radiographic progression-free survival. Started Jul 2026; status: active, not recruiting.
02
Drugs
BMS-986365
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250827.